InnoCan Pharma and DocMorris report divergent financial trends

InnoCan Pharma reported a 29.7 percent increase in revenue for the first quarter of 2026, reaching 6.47 million USD. CEO Iris Bincovich noted continuous growth and sustainable profitability across both the pharma and cosmetics business segments. Despite these figures and a reported 130 percent increase in operating results during the first half of 2025, the company's stock price has recently hit new lows, a trend attributed to general caution regarding biotech valuations rather than specific company news.

DocMorris is showing signs of an operational turnaround, with recent financial results exceeding expectations. The company's revenue grew by 13.2 percent to 295.4 million CHF, driven largely by a 45.8 percent surge in its prescription (Rx) business. Germany remains its strongest market, with revenues increasing by 13 percent. Additionally, DocMorris has successfully reduced its losses, with adjusted EBITDA improving from minus 28.8 million CHF to minus 10.9 million CHF in the first semester.